EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma

Rui Zhu, Zi-Xuan Zhang, Xin-Zhi Lu, Kui Mao

Frontiers in Oncology · 10.12.2025 · 15

DOI: 10.3389/fonc.2025.1710686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 10.12.2025. Verfasst von Rui Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First People's Hospital of Linhai, Linhai, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transarterial chemoembolization (TACE) and systemic therapy are frequently applied for advanced hepatocellular carcinoma (HCC), but their combined therapeutic potential remains uncertain. Here, the clinical efficacy and safety of TACE together with rivoceranib plus camrelizumab in Barcelona Clinic Liver Cancer (BCLC) stage C HCC were investigated.

Methods

Between January 2021 and December 2024, 167 consecutive cases of BCLC stage C HCC were retrospectively analyzed. Eighty-three received rivoceranib-camrelizumab with TACE, and 84 received rivoceranib-camrelizumab alone. Comparisons of baseline characteristics, tumor response, long-term outcomes, and adverse events were conducted.

Results

Baseline variables were balanced between groups. Combination therapy achieved significantly higher partial (39.8% vs. 20.2%, P = 0.006) and objective response rates (50.6% vs. 29.7%, P = 0.006) than systemic therapy alone. Median progression-free survival (PFS: 11.0 vs. 9.0 months, P = 0.008) and overall survival (OS: 19.0 vs. 15.0 months, P = 0.001) were both longer in the combination group. Cox regression identified combined treatment as an independent predictor of extended PFS and OS. Post-embolization symptoms occurred only in the TACE group but no grade 3-4 events were observed, and rates of systemic treatment-related adverse events were comparable between groups.

Conclusions

Adding TACE to rivoceranib-camrelizumab has the potential to improve tumor response and survival in BCLC stage C HCC without compromising safety.

Schlagwörter

Stichwörter der Autor:innen

camrelizumabhepatocellular carcinomainterventionrivoceranibtransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Interventional Radiology, The First People's Hospital of Linhai, Linhai, China.
  • Department of Radiology, Xuzhou Central Hospital, Xuzhou, China.
  • Department of General Surgery, The First People's Hospital of Linhai, Linhai, China.

Zitieren

APA

Zhu, R., Zhang, Z. X., Lu, X. Z., & Mao, K. (2025). Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1710686

Vancouver

Zhu R, Zhang ZX, Lu XZ, Mao K. Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1710686

BibTeX
@article{Zhu2025,
  author = {Zhu, Rui and Zhang, Zi-Xuan and Lu, Xin-Zhi and Mao, Kui},
  title = {Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1710686}
}
Kostenlos starten →